
StarMab BioMed’s First-in-Class, Dual-Target Anti-Tumor Drug SM2275 for Novel Immunotherapy Receives FDA IND Approval
StarMab announces that US FDA has approved its Investigational New Drug (IND) application for SM2275, a novel dual-target nanobody-based anti-tumor therapy. BEIJING, CHINA, April 7, 2025 /EINPresswire.com/ -- Beijing StarMab BioMed Technology , …